Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 927-936

  Infante, Jeffrey R ^a   Novello, Silvia ^b   Ma, Wen Wee ^c   Dy, Grace K ^c   Bendell, Johanna C ^a   Huff, Anne ^d   Wang, Qiong ^d   Suttle, A Benjamin ^d   Allen, Robert ^e   Xu, Chun Fang ^f   Ottesen, Lone H ^f   Burris III, Howard A ^a   Adjei, Alex A ^c  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Combination therapy; Maximum tolerated dose; Non small cell lung carcinoma; Pazopanib; Pemetrexed

Indexed keywords

CYSTATHIONINE; HOMOCYSTEINE; METHYLMALONIC ACID; PAZOPANIB; PEMETREXED; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ALLELE; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER TUMOR; BLOOD TOXICITY; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESOPHAGUS TUMOR; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GENE; GENETIC VARIABILITY; HEAD AND NECK TUMOR; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTRANSAMINASEMIA; KIDNEY TUMOR; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; THROMBOCYTOPENIA; THYMOMA; VEGFA GENE;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PYRIMIDINES; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84880922826     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9900-0     Document Type: Article

References (30)

1. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307. doi: 10.1038/nature10144
2. Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8:210-221. doi: 10.1038/nrclinonc.2011.21
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309
4. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13:1845-1857
5. Yuan A, Yu CJ, Kuo SH et al (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432-441
6. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380
7. Socinski MA, Novello S, Brahmer JR et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656. doi: 10.1200/JCO.2007.13.9303
8. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550. doi: 10.1056/NEJMoa061884
9. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234. doi: 10.1200/JCO.2007.14.5466
10. Patel JD, Hensing TA, Rademaker A et al (2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27:3284-3289. doi: 10.1200/JCO.2008.20.8181
11. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597. doi: 10.1200/JCO.2004.08.163
12. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551. doi: 10.1200/JCO.2007.15.0375
13. Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374:1432-1440. doi: 10.1016/S0140-6736(09)61497-5
14. Adjei AA, Mandrekar SJ, Dy GK et al (2010) Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 28:614-619. doi: 10.1200/JCO.2009.23.6406
15. Patel JD, Bonomi P, Socinski MA et al (2009) Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 10:252-256
16. Ulahannan SV, Brahmer JR (2011) Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 29:325-337
17. Kumar R, Knick VB, Rudolph SK et al (2007) Pharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6:2012-2021. doi: 10.1158/1535-7163.MCT-07-0193
18. Votrient (pazopanib) prescribing information. GlaxoSmithKline: Research Triangle Park, NC. Revised April 2012. http://www.accessdata.fda.gov/drugsatfda- docs/label/2012/022465s-010S-012lbl.pdf Accessed Oct 25, 2012
19. Altorki N, Lane ME, Bauer T et al (2010) Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 28:3131-3137
20. Friedlander M, Hancock KC, Rischin D et al (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119:32-37
21. Monk BJ, Mas Lopez L, Zarba JJ et al (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562-3569
22. Niyikiza C, Baker SD, Seitz DE et al (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552
23. Savage DG, Lindenbaum J, Stabler SP, Allen RH (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 96:239-246
24. Stabler SP, Lindenbaum J, Savage DG, Allen RH (1993) Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 81:3404-3413
25. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
26. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989
27. LaPlant KD, Louzon PD (2010) Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann Pharmacother 44:1054-1060
28. Fuld AD, Dragnev KH, Rigas JR (2010) Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother 11:1387-1402
29. Alimta (pemetrexed) prescribing information. Eli Lilly and Company: Indianapolis, IN. Revised November 2011. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021462s029s030s032lbl.pdf. Accessed March 19, 2012
30. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678